Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open-Label, Single-Arm, Single-Centre Study to Establish Proof of Mechanism, Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of IMM-01 as Monotherapy in Checkpoint Inhibitor Naïve Patients With Advanced Solid Tumours

Next Previous
X
Search
Trial Profile

A Phase I Open-Label, Single-Arm, Single-Centre Study to Establish Proof of Mechanism, Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of IMM-01 as Monotherapy in Checkpoint Inhibitor Naïve Patients With Advanced Solid Tumours

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMM 01 (Primary) ; Aldesleukin; Losartan
  • Indications Colorectal cancer; Head and neck cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Uveal melanoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Modulate Therapeutics

    • Most Recent Events

    • 04 Sep 2020 Status changed from planning to not yet recruiting.
    • 03 Feb 2016 New trial record
    • 01 Feb 2016 According to TVM Life Science media release, company is planning to file an Investigational New Drug (IND) application in 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top